Cargando…

GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients

PURPOSE: This study aimed to evaluate the safety and efficacy of chimeric antigen receptor (CAR) disialoganglioside 2 (GD2)-specific (4SCAR-GD2) T cells for treatment of refractory and/or recurrent neuroblastoma (NB) in pediatric patients. EXPERIMENTAL DESIGN: A phase I clinical study using 4SCAR-GD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Lihua, Huang, Lulu, Lin, Danna, Lai, Xiaorong, Wu, Li, Liao, Xu, Liu, Jiale, Zeng, Yinghua, Liang, Lichan, Zhang, Guanmei, Wang, Bin, Wu, Zhu, Tao, Shaohua, Liu, Yuchen, Jiao, Cheng, Chang, Lung-Ji, Yang, Lihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470713/ https://www.ncbi.nlm.nih.gov/pubmed/34724115 http://dx.doi.org/10.1007/s00432-021-03839-5

Ejemplares similares

A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing
por: Prapa, Malvina, et al.
Publicado: (2015)

Case Report: Reversible Hyperglycemia Following Rapamycin Treatment for Atypical Choroid Plexus Papilloma in an Infant
por: Liu, Jiale, et al.
Publicado: (2022)

Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma
por: Sawaisorn, Piamsiri, et al.
Publicado: (2020)

GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interaction
por: Sujjitjoon, Jatuporn, et al.
Publicado: (2020)

Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells
por: Yankelevich, Maxim, et al.
Publicado: (2023)

Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors
por: Golinelli, Giulia, et al.
Publicado: (2018)

Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
por: Reppel, Loïc, et al.
Publicado: (2022)

Preclinical testing of chimeric antigen receptor T cells in neuroblastoma mouse models
por: Li, Nan, et al.
Publicado: (2021)

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
por: Zhou, Xuan, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
por: Ding, Jing, et al.
Publicado: (2022)

Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
por: Mora, Jaume, et al.
Publicado: (2021)

Generation and Characterization of a Human/Mouse Chimeric GD(2)-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma
por: Eger, Christin, et al.
Publicado: (2016)

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
por: Yu, Jiayi, et al.
Publicado: (2018)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)

Case report: Compound heterozygous mutations in the KDSR gene cause progressive keratodermia and thrombocytopenia
por: Wu, Li, et al.
Publicado: (2022)

Poor outcome of pediatric B-cell acute lymphoblastic leukemia associated with high level of CRLF2 gene expression in distinct molecular subtypes
por: Lin, Danna, et al.
Publicado: (2023)

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2017)

An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma
por: Tian, Meijie, et al.
Publicado: (2022)

Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients
por: Lode, Holger, et al.
Publicado: (2013)

Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma
por: Tomida, Akimasa, et al.
Publicado: (2021)

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
por: Tu, Sanfang, et al.
Publicado: (2019)

Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia
por: Terme, Mickaël, et al.
Publicado: (2014)

Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins
Publicado: (1986)

Correction: Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia
Publicado: (2014)

GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells
por: Seitz, Christian M., et al.
Publicado: (2019)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
por: Chan, Godfrey Chi-Fung, et al.
Publicado: (2022)

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2021)

P1466: CD7 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR ADULT PATIENTS WITH REFRACTORY AND RELAPSED T CELL MALIGNANCIES
por: Zhang, Y., et al.
Publicado: (2022)

Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2020)

Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting
por: Sabbih, Godfred O., et al.
Publicado: (2021)

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
por: Paret, Claudia, et al.
Publicado: (2022)

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies
por: Zheng, Diwei, et al.
Publicado: (2022)

Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
por: Potnis, Kunal C., et al.
Publicado: (2022)

A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics
por: Zhang, Liyu, et al.
Publicado: (2021)

Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma
por: Liu, Zhuohao, et al.
Publicado: (2023)

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
por: Gu, Runxia, et al.
Publicado: (2020)

New Chimeric Antigen Receptor Design for Solid Tumors
por: Wang, Yuedi, et al.
Publicado: (2017)

Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy
por: Qiu, Lei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ti9fkj3j7quthsrgv1ld0vtd3n